Salestools LogoSalestools
Salestools LogoSalestools
Biotech

Denali Therapeutics

Denali Therapeutics raises $217M Series C at $5B valuation

$217M
Total Raised
Series C
Latest Round
2015
Founded
600+
Employees
161 Oyster Point Boulevard, South San Francisco, CA 94080
1 min read

Quick Facts

Valuation
$5B
Latest Round Size
$217M
Latest Round Date
March 2024

Denali Therapeutics: Series C Funding Round

Denali Therapeutics has successfully raised $217M in Series C funding, reaching a valuation of $5B.

Company Overview

Neurodegeneration therapeutics

Funding Details

The Series C round was led by Baillie Gifford, with participation from Redmile Group, Vivo Capital, GV, Fidelity.

Company Information

  • Headquarters: 161 Oyster Point Boulevard, South San Francisco, CA 94080
  • Founded: 2015
  • Employees: 600+
  • Category: Biotech

Investment

Denali Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Baillie Gifford: Verified investor in Series C
  • Redmile Group: Verified investor in Series C
  • Vivo Capital: Verified investor in Series C
  • GV: Verified investor in Series C
  • Fidelity: Verified investor in Series C

Key Investors

Baillie Gifford
Lead Investor
Verified investor in Series C
Redmile Group
Investor
Verified investor in Series C
Vivo Capital
Investor
Verified investor in Series C
GV
Investor
Verified investor in Series C
Fidelity
Investor
Verified investor in Series C

Topics

verified(3080)real-funding(3080)series-c(264)biotech(108)denali-therapeutics(1)161-oyster-point-boulevard(1)

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources

Related Company Reports

Biotech
Torl Biotherapeutics

Torl Biotherapeutics raises $96M Series C at $500M valuation

Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...

Editorial Team
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics

Nilo Therapeutics raises $101M Series A at $450M valuation

Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...

Editorial Team
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics

Arthrosi Therapeutics raises $153M Series E at $800M valuation

Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...

Editorial Team
Editorial Team
Oct 8, 2025
1 min read•$153M